Clinical trial

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

NCT04075266

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-01-09

PhasePHASE2

Study timeline

Study start (actual)2020-01-09Date precision: day

Registry last updated2026-09-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

OcrelizumabDRUG · verified · RxNorm: ocrelizumab

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

WarsawPoland2 BostonMassachusetts, United States1 St LouisMissouri, United States1 ClevelandOhio, United States1 Washington D.C.District of Columbia, United States1 AuroraColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04075266 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.